Biology of Blood and Marrow Transplantation
Volume 13, Issue 5 , Pages 601-607 , May 2007

Equivalent Survival for Sibling and Unrelated Donor Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia

  • John Moore

      Affiliations

    • Haematology Department, St. Vincent’s Hospital, Darlinghurst, NSW, Australia
    • Corresponding Author InformationCorrespondence and reprint requests: John Moore, MBBS, MD, FRACP, FRCPA, Haematology Department, St. Vincent’s Hospital, Darlinghurst, NSW Australia.
    • ,
  • Ian Nivison-Smith

      Affiliations

    • Australasian Bone Marrow Transplant Recipient Registry, Darlinghurst, NSW, Australia
    • ,
  • Kim Goh

      Affiliations

    • National University of Malaysia, Kuala Lumpur, Malaysia
    • ,
  • David Ma

      Affiliations

    • Haematology Department, St. Vincent’s Hospital, Darlinghurst, NSW, Australia
    • ,
  • Ken Bradstock

      Affiliations

    • BMT Service, Westmead Hospital, Westmead, NSW, Australia
    • ,
  • Jeff Szer

      Affiliations

    • Bone Marrow Transplant Service, Department of Clinical Haematology and Medical Oncology, Royal Melbourne Hospital, Parkville, Victoria, Australia
    • ,
  • Simon Durrant

      Affiliations

    • Haematology Department, Royal Brisbane Hospital, Brisbane, Queensland, Australia
    • ,
  • Anthony Schwarer

      Affiliations

    • Haematology Department, Alfred Hospital, Prahran, Victoria, Australia
    • ,
  • Peter Bardy

      Affiliations

    • Haematology Department, Royal Adelaide Hospital, Adelaide, South Australia
    • ,
  • Richard Herrmann

      Affiliations

    • Haematology Department, Royal Perth Hospital, Perth, Western Australia
    • ,
  • Anthony Dodds

      Affiliations

    • Haematology Department, St. Vincent’s Hospital, Darlinghurst, NSW, Australia

Received 6 April 2006 ,Accepted 15 January 2007.

References 

  1. Armitage JO. Bone marrow transplantation. N Engl J Med. 1994;330:827–838
  2. Nivison-Smith I, Bradstock KF, Dodds AJ, Hawkins PA, Szer J. Haemopoietic stem cell transplantation in Australia and New Zealand, 1992-2001: progress report from the Australasian Bone Marrow Transplant Recipient Registry. Int Med J. 2005;35:18–27
  3. Burnett AK, Wheatley K, Goldstone AH, et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol. 2002;118:385–400
  4. Michallet M, Thomas X, Vernant JP, et al. Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Societe Francaise de Greffe de Moelle (SFGM). Bone Marrow Transplant. 2000;26:1157–1163
  5. Szydlo R, Goldman JM, Klein JP, et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol. 1997;15:1767–1777
  6. Weisdorf DJ, Anasetti C, Antin JH, et al. Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. Blood. 2002;99:1971–1977
  7. Flomenberg N, Baxter-Lowe LA, Confer D, et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood. 2004;104:1923–1930
  8. Keating S, Suciu S, de Witte T, et al. The European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell’ Adulto (GIMEMA) Leukemia Cooperative Groups Prognostic factors of patients with acute myeloid leukemia (AML) allografted in first complete remission: an analysis of the EORTC-GIMEMA AML 8A trial. Bone Marrow Transplant. 1996;17:993–1001
  9. Ringden O, Labopin M, Bacigalupo A, et al. Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia. J Clin Oncol. 2002;20:4655–4664
  10. Loberiza F. Summary slides 2003-Part II. IBMTR/ABMTR newsletter. 2004;Volume 10(2):6
  11. Greinix HT, Nachbaur D, Krieger O, et al. Factors affecting long-term outcome after allogeneic haematopoietic stem cell transplantation for acute myelogenous leukaemia: a retrospective study of 172 adult patients reported to the Austrian Stem Cell Transplantation Registry. Br J Haematol. 2002;117:914–923
  12. Boeckh M, Leisenring W, Riddell SR, et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood. 2003;101:407–414
  13. Peggs K, Mackinnon S. Imatinib mesylate—the new gold standard for treatment of chronic myeloid leukemia. N Engl J Med. 2003;348:1048–1050
  14. Eapen M, Rubinstein P, Zhang MJ, et al. Comparable long-term survival after unrelated and HLA-matched sibling donor hematopoietic stem cell transplantations for acute leukemia in children younger than 18 months. J Clin Oncol. 2006;24:145–151
  15. Bertz H, Potthoff K, Finke J. Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia. J Clin Oncol. 2003;21:1480–1484
  16. Yakoub-Agha I, Mesnil F, Kuentz M, et al. Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy. J Clin Oncol. 2006;24:5695–5702
  17. Litzow MR, Perez WS, Klein JP, et al. Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide-total body irradiation versus busulphan-cyclophosphamide conditioning regimens for acute myelogenous leukaemia in first remission. Br J Haematol. 2002;119:1115–1124M
  18. Nivison-Smith I, Bradstock KF, Szer J, et al. Allogeneic haemopoietic cell transplants in Australia, 1996—a multi-centre retrospective comparison of the use of peripheral blood stem cells with bone marrow. Bone Marrow Transplant. 2001;28:21–27
  19. Boeckh M, Nichols WG. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood. 2003;103:2003–2008
  20. Craddock C, Szydlo RM, Dazzi F, et al. Cytomegalovirus seropositivity adversely influences outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft-versus-host disease prophylaxis. Br J Haematol. 2001;112:228–236

PII: S1083-8791(07)00118-8

doi: 10.1016/j.bbmt.2007.01.073

Biology of Blood and Marrow Transplantation
Volume 13, Issue 5 , Pages 601-607 , May 2007

Article Tools

* Image Usage & Resolution